Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
NCT05708859 on ClinicalTrials.gov · last registry update 2024-10-15
Recruiting now, toward 120 participants. Its estimated completion date, December 2025, has passed with no update to the record. Primary outcome, as filed: Reduction of total non-calcified coronary plaque volume. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Matthew J. Budoff
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2024-01-02
- Primary completion
- 2025-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Reduction of total non-calcified coronary plaque volume
Conditions studied
Type II Diabetes · Atherosclerosis
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.